Company Description
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
The company was incorporated in 2005 and is headquartered in Calabasas, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Amir Heshmatpour |
Contact Details
Address: 23975 Park Sorrento, Suite 205 Calabasas, California 91302 United States | |
| Phone | 310 663 7831 |
| Website | neonc.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1979414 |
| CUSIP Number | 64051A101 |
| ISIN Number | US64051A1016 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amir Farrokh Heshmatpour | President, Chief Executive Officer, Executive Chairman and Secretary |
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Medical Officer, Chief Scientific Officer and Vice Chairman |
| Keithly A. Garnett | Chief Financial Officer |
| Dr. Josh Neman-Ebrahim Ph.D. | Chief Clinical Officer |
| David Choi Jr. | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2026 | 8-K | Current Report |
| Jun 25, 2026 | D | Notice of Exempt Offering of Securities |
| Jun 23, 2026 | EFFECT | Notice of Effectiveness |
| Jun 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 23, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 23, 2026 | 8-K | Current Report |
| Jun 23, 2026 | 424B5 | Filing |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 15, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 12, 2026 | 8-K | Current Report |